What is PepGen?
Founded in 2018 and headquartered in Cambridge, Massachusetts, PepGen is at the forefront of the biotechnology sector, specifically focusing on the development of oligonucleotide therapeutics. The company's core mission is to transform the treatment paradigm for patients suffering from severe neuromuscular and neurologic diseases. By utilizing advanced delivery technologies, PepGen aims to overcome the historical barriers associated with the systemic delivery of genetic therapies, thereby enhancing therapeutic efficacy and patient outcomes.
The firm occupies a critical niche in the life sciences market, bridging the gap between academic research and commercial-scale drug development. Its market position is bolstered by a robust intellectual property portfolio and strategic partnerships that facilitate the translation of complex scientific discoveries into viable clinical candidates. As a clinical-stage entity, PepGen is currently focused on validating its platform through rigorous human trials, aiming to establish a new standard of care for rare and debilitating genetic disorders.
How much funding has PepGen raised?
PepGen has raised a total of $56.3M across 2 funding rounds:
Series A
$45M
Unspecified
$11.3M
Series A (2020): $45M with participation from RA Capital Management LP, CureDuchenne, Oxford University, and Oxford Sciences Enterprises
Unspecified (2021): $11.3M led by Viking Global Investors, RA Capital Management, Oxford Sciences Enterprises, and CureDuchenne
Key Investors in PepGen
Oxford Sciences Enterprises
An independent investment firm that builds transformational businesses through a unique partnership with the University of Oxford, focusing on high-impact scientific ventures.
CureDuchenne
A nonprofit organization utilizing a venture philanthropy model to fund innovative research and accelerate the development of treatments for Duchenne muscular dystrophy.
Viking Global Investors
A global investment firm that employs fundamental analysis to select long-term equity interests across various industries, including the life sciences sector.
What's next for PepGen?
Looking ahead, the recent capital infusion will likely be deployed to expand PepGen's clinical trial infrastructure and accelerate the progression of its lead therapeutic candidates. The company is expected to prioritize the scaling of its manufacturing capabilities and the deepening of its research pipeline to address a broader spectrum of neurologic indications. Given the current market environment for biotech, PepGen's ability to maintain its momentum will depend on the successful readout of its ongoing clinical studies and the continued support of its diverse investor base. The strategic focus remains on achieving key regulatory milestones that will validate the long-term commercial viability of its oligonucleotide platform.
See full PepGen company page
